Empresa líder na fabricação de APIs farmacêuticas
Who we are
At Dr. Reddy’s, we believe that access to affordable, high-quality medicines starts with world-class APIs.
At Dr. Reddy’s, we enable access to affordable, high-quality medicines through our trusted API portfolio. With 250+ APIs supplied across 80+ countries, we are a preferred partner to leading generic manufacturers worldwide including in the U.S., Europe, Latin America, Japan, China, Korea, and emerging markets.
Backed by 40+ years of scientific excellence, we specialize in complex APIs such as steroids, peptides, long-chain molecules, and highly potent oncology drugs. Our deep R&D capabilities, strong IP management, and rigorous regulatory compliance ensure speed-to-market, reliability, and quality.
We prioritize sustainable innovation and operational excellence, helping our partners stay ahead in competitive markets. Together, we’re shaping a healthier future.
Our Journey
2021
Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
We combined our in-house efforts with an open-innovation model of partnerships to make available a portfolio that included a vaccine, and therapeutics for mild, moderate, and severe COVID-19.
Our focus on agility, access, and affordability helped us reach over 5 million patients during the pandemic, especially in low- and middle-income countries.
2022
Our biggest manufacturing facility in Hyderabad was recognized by the World Economic Forum as part of its Global Lighthouse Network for leadership in the use of Industry 4.0 technologies.
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
We refreshed our ESG goals to make them bold, measurable, accountable, and central to business strategy.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech.
We launched Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-file, 180-day exclusivity
2023
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management, marking our foray into digital therapeutics.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
2024
We diversified our offerings to patients – women’s healthcare in the U.S., consumer healthcare and our first-ever biosimilar in the UK, and vaccines in India.
We agreed with Nestlé India to form a joint venture to introduce health science nutraceutical products to consumers across India and other agreed territories.
We signed a definitive agreement with Haleon plc to acquire Nicotinell and its related portfolio in Nicotine Replacement Therapy, in a significant step towards building a global consumer healthcare business, outside of the US. This is our biggest acquisition yet.
Sustainability & Strength -pt
- Bloomberg Gender-Equality Index – 6th consecutive year
- EcoVadis Gold Medal for sustainability
- Express Pharma Excellence Award 2025 – Export Powerhouse
- USD 405.6 million API revenue
- 111 new DMFs filed globally -pt
Excellence and Legacy
Years of serving patients
Active pharmaceutical Ingredients
DMFs filed globally
Research scientists working on various projects
Countries (Global Presence)
Employees Globally (57 Nationalities)
Patients access our therapies every year
Billion USD revenue
Abbreviated New Drug Applications (ANDAs)
Our Promises
Bringing essential medicines within reach
Addressing unmet patient needs
Addressing unmet patient needs
Working with partners to help them succeed
Helping patients manage disease better
Our Team
Deepak Sapra
Executive Vice President & Head - SEAMEA & B2B Formulations
Deepak Sapra
Deepak Sapra is a distinguished business leader, author, and social entrepreneur, currently CEO of PSAI at Dr. Reddy’s Laboratories and board member at APSL (a subsidiary of Dr. Reddy’s Laboratories). An IIM Bangalore and IRIMEE alumnus. He has also been awarded prestigious international fellowships, including the Chevening Scholarship (UK) and the Fulbright Fellowship (USA). He co-founded Priyajan, driving inclusive development in rural India. Through his diverse portfolio of leadership, writing, and community initiatives, he continues to shape both the business and human sides of healthcare and public service.
Dr. A Kalyan Chakravarthy
Executive Vice President & Head - SEAMEA & B2B Formulations
Dr. A Kalyan Chakravarthy
Dr. A. Kalyan Chakravarthy is a seasoned pharmaceutical leader with over two decades of experience in drug development, formulation innovation & regulatory affairs. He currently serves as Executive Vice President and Head – SEMEA and B2B Formulations. Before his current role, he was Vice President & Head – B2B Formulations, after beginning his leadership journey at Sai Life Sciences as Associate Director & Head of Regulatory Affairs (India Operations). His tenure in the pharmaceutical industry reflects a deep understanding of technical, operational, and regulatory complexities spanning both emerging and developed markets.
Amit Parekh - pt
Vice President & Head of Finance, PSAI -pt
Amit Parekh - pt
Azhar is a seasoned leader with over 18 years of experience in business building, digital transformation, strategy, and product leadership. Azhar delivered value for customers and stakeholders across various sectors and geographies, including financial services / FinTech, healthcare, e-commerce marketplaces (B2B / B2C / D2C / O2O), retail, and consulting. In his current role as the Global Head of Digital & Technology (PSAI) at Dr. Reddy's Laboratories, he leads the customer success and business growth for the region, as well as builds a digital platform business and leads digital transformation and technology initiatives across the organization. -pt
Dr. Reddy’s Global Management Council
To read about the leaders of the organisation worldwide at Dr. Reddy’s website
Know More
Sustainability message
from the CEO
Sustainability is at the core of our mission at Dr. Reddy’s. We are committed to minimizing our environmental footprint, empowering communities, and ensuring ethical business practices. Together, we can build a healthier planet for future generations.